Beacon Pointe Advisors, LLC Intra Cellular Therapies, Inc. Transaction History
Beacon Pointe Advisors, LLC
- $8.55 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding ITCI
# of Institutions
390Shares Held
88.9MCall Options Held
202KPut Options Held
114K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.24 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$809 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$656 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$416 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$411 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.1B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...